New Drugs Approved for Treating Hypercholesterolemia

Unique mechanisms of action

Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor. MTP resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B–containing lipoproteins in enterocytes and hepatocytes. This inhibition leads to a reduction in the synthesis of chylomicrons and very low–density lipoprotein, resulting in a reduction in plasma LDL levels. This is the first MTP inhibitor approved by FDA for any indication.
Mipomersen is an oligonucleotide inhibitor of apo B-100 synthesis that reduces LDL cholesterol by preventing the formation of atherogenic lipids. It decreases the production of apo B, which provides the structural core for all atherogenic lipids, including LDL cholesterol, which carry cholesterol through the bloodstream.

VERY COOL! :)

Ref: Pharmacy Today 2013 (APhP)